Phase 1 Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 4 to 80 years
- People who have been diagnosed with a high-risk blood cancer — specifically acute lymphocytic leukemia, acute myeloid leukemia, ambiguous lineage leukemia, or myeloma — where the disease has come back or has not responded to treatment
- People who have a performance score of 50 or higher on the Karnofsky or Lansky scale, which measures how well a person is able to carry out daily activities (confirm with trial site)
- People who agree to use contraception during the study, where this applies based on age
- People (or their parent or guardian, for younger participants) who are able to give informed consent to take part
- People who are able to undergo a special type of imaging scan called an 18F FLT scan without needing sedation
- People whose liver and kidney function test results fall within the ranges required by the trial (confirm specific values with trial site)
- People whose blood oxygen level, measured by a pulse oximetry device, is above 90% while breathing normal room air
- People who are receiving immunotherapy (Arm A) or other non-immune cancer treatments such as chemotherapy or certain types of radiotherapy — but not a stem cell transplant (Arm B)
Who may not be able to join:
- People who have an infection that is not under control
- People who are pregnant or currently breastfeeding
- People who have previously had an allergic reaction or intolerance to fluorothymidine, which is the substance used in the imaging scan
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Jennifer Holter, MD, Stephenson Cancer Center
Phone: 1-405-271-8777
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Proportion of 18F FLT signal uptake abnormalities with clinical pathology reports for determining the evidence of hematopoietic disease.; A proportion of 18F FLT uptake in a standard region of interest in marrow to objectively identify disease status in patient with hematopoietic cancers.; Mean differences of 18F FLT uptake to determine extramedullary disease.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.